Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences

Alkermes announced the presentation of accepted research at five major spring scientific conferences, including the American Psychiatric Association (APA) and ISPOR. The presentations focus on real-world evidence and clinical data for its psychiatry portfolio, specifically LYBALVI and ARISTADA, highlighting treatment adherence, persistence, and relapse rates in schizophrenia and bipolar I disorder.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.